ReviewFrontiers in medicine2022
The dual role of CD6 as a therapeutic target in cancer and autoimmune disease.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab.Journal for immunotherapy of cancer · 2026Article
- Association of Vitamin D Levels and Systemic Inflammation in Patients with Hashimoto's Thyroiditis.Diseases (Basel, Switzerland) · 2026Article
- Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma.Molecular cancer therapeutics · 2026Article
- Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells.Science advances · 2025Article
- Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.Immunity, inflammation and disease · 2025Review
- ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.NPJ precision oncology · 2025Article
- Pediatric Atopic Dermatitis Exhibits Distinctive Patterns in JAK/STAT Pathway Activation and CD6-ALCAM Signaling.Immune network · 2025Article
- Identification of Deregulated Proteins in MutatedCancers · 2025Article
- A transcriptome-based human universal senescence index (hUSI) robustly predicts cellular senescence under various conditions.Nature aging · 2025Article
- CD6 in Human Disease.Cells · 2025Review
- Single-cell RNA-sequencing and spatial transcriptomic analysis reveal a distinct population of APOEClinical and translational medicine · 2025Article
- Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines.Frontiers in immunology · 2025Article
- The OT-II model reveals dualFrontiers in immunology · 2025Article
- Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.Cancer immunology, immunotherapy : CII · 2024Article
- Ligands of CD6: roles in the pathogenesis and treatment of cancer.Frontiers in immunology · 2024Review
- CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.International journal of molecular sciences · 2023Review
- Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells.Research square · 2023Article
- Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.